Immune responses to lentiviral vectors
- PMID: 17979677
- DOI: 10.2174/156652307782151515
Immune responses to lentiviral vectors
Abstract
Efficient delivery and sustained expression of a therapeutic gene into human tissues are the requisite to accomplish the high expectations of gene therapy. A major challenge has concerned development of gene transfer systems capable of efficient cell transduction and transgene expression without harm to the recipient. A lot of work has been done to demonstrate the efficacy of gene therapy in animal models that mimic situations in humans. Use of lentiviral vectors (LVs) offers multiple advantages for gene replacement therapy, because they combine efficient delivery, ability to transduce proliferating and resting cells, capacity to integrate into the host chromatin to provide stable long-term expression of the transgene, absence of any viral genes in the vector and absence of interference from preexisting viral immunity. However, one of the major barriers to stable gene transfer by LVs and other viral vectors is the development of innate and adaptive immune responses to the delivery vector and the transferred therapeutic transgene. Since this greatly hinders the therapeutical benefits of gene therapy by LVs, developing strategies to overcome the host immune response to the transfer vector and the transgene is a matter of current investigation.
Similar articles
-
Immune responses to adenovirus and adeno-associated vectors used for gene therapy of brain diseases: the role of immunological synapses in understanding the cell biology of neuroimmune interactions.Curr Gene Ther. 2007 Oct;7(5):347-60. doi: 10.2174/156652307782151498. Curr Gene Ther. 2007. PMID: 17979681 Free PMC article. Review.
-
Modulation of immune responses in lentiviral vector-mediated gene transfer.Cell Immunol. 2019 Aug;342:103802. doi: 10.1016/j.cellimm.2018.04.012. Epub 2018 Apr 27. Cell Immunol. 2019. PMID: 29735164 Free PMC article. Review.
-
Stability of lentiviral vector-mediated transgene expression in the brain in the presence of systemic antivector immune responses.Hum Gene Ther. 2005 Jun;16(6):741-51. doi: 10.1089/hum.2005.16.741. Hum Gene Ther. 2005. PMID: 15960605 Free PMC article.
-
New Methods for Disease Modeling Using Lentiviral Vectors.Trends Mol Med. 2018 Oct;24(10):825-837. doi: 10.1016/j.molmed.2018.08.001. Epub 2018 Sep 10. Trends Mol Med. 2018. PMID: 30213701 Review.
-
Evading the immune response upon in vivo gene therapy with viral vectors.Curr Opin Mol Ther. 2009 Oct;11(5):493-503. Curr Opin Mol Ther. 2009. PMID: 19806497 Free PMC article. Review.
Cited by
-
CRISPR-Cas9 directed knock-out of a constitutively expressed gene using lance array nanoinjection.Springerplus. 2016 Sep 9;5(1):1521. doi: 10.1186/s40064-016-3037-0. eCollection 2016. Springerplus. 2016. PMID: 27652094 Free PMC article.
-
Seeing the Future: A Review of Ocular Therapy.Bioengineering (Basel). 2024 Feb 13;11(2):179. doi: 10.3390/bioengineering11020179. Bioengineering (Basel). 2024. PMID: 38391665 Free PMC article. Review.
-
CRISPR/Cas9 for Cancer Therapy: Hopes and Challenges.Biomedicines. 2018 Nov 12;6(4):105. doi: 10.3390/biomedicines6040105. Biomedicines. 2018. PMID: 30424477 Free PMC article. Review.
-
[Construction and identification of a HEK293 cell line with stable TrxR1 overexpression].Nan Fang Yi Ke Da Xue Xue Bao. 2022 Apr 20;42(4):554-560. doi: 10.12122/j.issn.1673-4254.2022.04.11. Nan Fang Yi Ke Da Xue Xue Bao. 2022. PMID: 35527491 Free PMC article. Chinese.
-
Use of DAF-displaying adenovirus vectors reduces induction of transgene- and vector-specific adaptive immune responses in mice.Hum Gene Ther. 2011 Sep;22(9):1083-94. doi: 10.1089/hum.2010.218. Epub 2011 Apr 18. Hum Gene Ther. 2011. PMID: 21388344 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
